129 results
8-K
EX-99.2
EDIT
Editas Medicine, Inc.
14 Jun 24
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
6:04am
, durable medicine that can provide life-changing clinical benefits to patients,” said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine. “I
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
14 Jun 24
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
6:04am
-changing clinical benefits to patients,” said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine. “Importantly, we continue to make
S-3ASR
EX-1.2
wgimmmh njw
28 Feb 24
Automatic shelf registration
5:13pm
S-3ASR
EX-4.4
ku9gzz2wuit0a8
28 Feb 24
Automatic shelf registration
5:13pm
S-3ASR
av4pgd
28 Feb 24
Automatic shelf registration
5:13pm
S-3ASR
EX-4.5
d368kxmel5100i8xz6pi
28 Feb 24
Automatic shelf registration
5:13pm
8-K
EX-99.1
5gg2xwe
11 Dec 23
Regulation FD Disclosure
4:23pm
8-K
gc27 231yf
22 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
EX-10.1
2rkucuvg6iancc6
22 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
EX-99.1
vln 9indt
3 Nov 23
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
7:06am